KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Account Payables (2016 - 2025)

Emergent BioSolutions' Change in Account Payables history spans 16 years, with the latest figure at $11.4 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 211.76% year-over-year to $11.4 million; the TTM value through Dec 2025 reached -$8.4 million, up 74.55%, while the annual FY2025 figure was -$8.4 million, 74.55% up from the prior year.
  • Change in Account Payables reached $11.4 million in Q4 2025 per EBS's latest filing, up from -$4.0 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $31.0 million in Q1 2023 to a low of -$23.0 million in Q3 2024.
  • Average Change in Account Payables over 5 years is -$2.3 million, with a median of -$4.4 million recorded in 2021.
  • Peak YoY movement for Change in Account Payables: tumbled 1200.0% in 2021, then soared 310.88% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at -$5.1 million in 2021, then soared by 56.86% to -$2.2 million in 2022, then plummeted by 222.73% to -$7.1 million in 2023, then tumbled by 43.66% to -$10.2 million in 2024, then skyrocketed by 211.76% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Change in Account Payables are $11.4 million (Q4 2025), -$4.0 million (Q3 2025), and -$10.4 million (Q2 2025).